Key points are not available for this paper at this time.
Interview with Dr. Peter Neumann on the use of various new value-based frameworks for assessing drugs and drug prices. (08:22)Download Escalating drug prices have spawned a flurry of initiatives designed to help physicians, payers, and patients understand the value of new therapies and make better choices about their use. But these efforts have revealed numerous analytic and implementation challenges.
Neumann et al. (Wed,) studied this question.